Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

Print Friendly, PDF & Email

NASH/DIABETES 2 RELATED: New results from the Phase 2a STAMP-NAFLD trial show consistently greater response in high-risk patients with coexisting type 2 diabetes (T2DM), estimated to be approximately 50% of NASH patients 1 Clinically meaningful improvements (p<0.05) in liver fat content, liver enzymes alanine transaminase (ALT) and aspartate transaminase (AST), fasting glucose […]